{
  "id": 3969767,
  "title": "Pinion Immunotherapeutics Publishes Preclinical Data Supporting Clinical-Ready RNA Immunotherapy for HPV-16 Cervical Precancer",
  "url": "https://urgent.news/2026/08/28/pinion-immunotherapeutics-publishes-preclinical-data-supporting",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-28T13:14:12.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/pinion-immunotherapeutics-publishes-preclinical-data-supporting-clinical-ready-rna-immunotherapy-for-hpv-16-cervical-precancer"
  },
  "original_language": "en",
  "account": null,
  "summary": "NORTH BETHESDA, Md. — Pinion Immunotherapeutics has published preclinical data supporting ARV-2001, its lead RNA immunotherapy, in the peer-reviewed journal Vaccines. With an Investigational New Drug application cleared by the FDA, Pinion is ready to begin clinical development for women with HPV-16-positive high-grade cervical precancer (CIN2/3). ARV-2001 is designed to clear precancerous lesions…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}